Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines현재 사용 가능한 COVID-19 백신에 저항할 가능성이 있는 새로 분류된 관심 변종인 SARS-CoV-2 Mu에 대처하기 위한 전략Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adopted approach B.1 lineage B.1.621 BNT161b2 booster dose Characteristics coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine COVID-19 vaccine development Evidence exacerbated Genetic genomic Genomic surveillance global mass vaccination Health implementation infections Intervention Lineage mass vaccination Mu variant mutations Neutralizing non-pharmaceutical interventions (NPIs) NPIs potential risk public health measure public health measures Recombination reported required respiratory restrict SARS-CoV-2 SARS-CoV-2 B.1.621 SARS-CoV-2 virus sera shown Strains Strategy sub-lineage B.1.621.1 Surveillance survivor the SARS-CoV-2 virus therapeutic threat vaccination Vaccine vaccine breakthrough. Vaccine development variant variants [DOI] 10.1080/21645515.2022.2027197 PMC 바로가기 [Article Type] Article
Probing marine brown macroalgal phlorotannins as antiviral candidate against SARS-CoV-2: molecular docking and dynamics simulation approachArticle Published on 2022-12-012022-11-15 Journal: Molecular diversity [Category] COVID19(2023년), SARS, 치료제, [키워드] 3CLpro antagonist Antiviral antiviral intervention approach AutoDock binding affinities binding affinity candidate Compound compounds COVID-19 COVID-19 therapeutics Cys145 deviation docking Drug discovery drug-likeness Efficacy evaluated GLN189 Glu166 immunostimulatory inhibit interaction site MD simulation molecular molecular docking Molecular docking and dynamics simulation over Phlorotannin polyphenol Probing RdRP reported SARS-CoV-2 SARS-CoV-2 replication SARS-CoV-2. selected target protein target proteins targets therapeutic Thr190 were assessed [DOI] 10.1007/s11030-022-10383-y PMC 바로가기
The spectrum of clinical biomarkers in severe malaria and new avenues for explorationArticle Published on 2022-12-012022-11-15 Journal: Virulence [Category] 바이오마커, [키워드] Biomarker Biomarkers C-reactive protein clinical evaluation clinical infections Clinical practice complement COVID-19 pandemic diagnostic Endemic Evidence Factor faster highlight host response Infection infections malaria MOST non-specific omics technology pathogen patients Plasmodium Plasmodium falciparum Platelet Pneumonia practicality Prognosis prognostic Prognostic biomarkers Protein public health Research Sample size severe malaria the disease therapeutic therapeutic. [DOI] 10.1080/21505594.2022.2056966 PMC 바로가기
SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including OmicronSARS-CoV-2 융합 억제 리포펩티드는 오미크론을 포함한 다양한 관심 변종에 대해 높은 효능을 유지합니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] activity Alpha antiviral activity Beta broad-spectrum antiviral broad-spectrum antivirals Cell Cell fusion cell-cell fusion combating COVID-19 pandemic D614G Delta drugs effective vaccine Effective vaccines exhibited FIVE fusion inhibitor Gamma Impact Infection inhibiting inhibitor inhibitors Lambda lipopeptide maintain mutant omicron Omicron variant other variant other variants outbreak pseudovirus pseudovirus pseudovirus infection pseudoviruses reduced S protein S proteins SARS-CoV-2 significantly the S protein therapeutic variant variants variants of concern variants of concern. VoC VOCs wild-type WT virus [DOI] 10.1080/22221751.2022.2098060 PMC 바로가기 [Article Type] Article
Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significanceArticle Published on 2022-12-012022-11-15 Journal: International journal of biological macromolecules [Category] COVID19(2023년), SARS, 유전자 메커니즘, 치료제, [키워드] Antiviral biological processe China complications death disease Evidence extreme feasible Giving globe immune reaction increase Infection mechanism Molecular biology ncRNA ncRNAs non-coding RNA noncoding RNA Pathogenesis pathogenic virus preventing infection Progress Research resulting RNA SARS-CoV-2 SARS-CoV2 Spread subsequent Symptoms therapeutic therapy Therapy. virus virus infection [DOI] 10.1016/j.ijbiomac.2022.09.105 PMC 바로가기
Potential interactions between antineoplastic agents and medicines used to treat Covid-19Article Published on 2022-12-012022-11-15 Journal: Journal of Oncology Pharmacy Practice [Category] 치료제, [키워드] accounted Affect antineoplastic agents antineoplastic drug Baricitinib benefit Cancer Chloroquine Combination conducted COVID-19 disease drug drug combinations drug-drug interaction Drug-drug interactions Drug–drug interactions drug–drug interactions. Health Hydroxychloroquine identify Interaction interaction effect interactions involved Lexicomp Medicine Modification outcomes Patient Patients with cancer pharmacokinetic pharmacological intervention plasma concentration Potential professional risk severity therapeutic treat Treatment tyrosine kinase inhibitor was increased [DOI] 10.1177/10781552211040494 PMC 바로가기
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19코로나19 중증도에 따라 항체 표적 SARS-CoV-2 에피토프 레퍼토리 달라Article Published on 2022-12-012022-09-11 Journal: Virulence [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] antibodies antibody Antigen association Asymptomatic asymptomatic individual asymptomatic infection Betacoronavirus betacoronavirus Community convalescent correlated COVID-19 COVID-19 severity develop diagnosed diagnostics disease severity domains Epitopes Evidence evidence of finding FIVE five groups HKU1 Hospitalization IgG IgGs Immunity immunogenic immunogenic peptide individual Infection less MERS-CoV nucleocapsid protein Nucleocapsid proteins OC43 participant pathogenic pathogenic mechanisms peptide peptide array peptides pilot study predicted Protein RBDs reaction Receptor binding domain Region repertoire SARS-CoV RBD SARS-CoV RBDs SARS-CoV-2 SARS-CoV-2 epitope SARS-CoV-2 epitopes seroconverted Seroprevalence seroprevalence. severity severity of COVID-19 symptomatic symptomatic COVID-19 symptomatic infection therapeutic therapeutic antibodies Vaccines Viral with COVID-19 without symptoms [DOI] 10.1080/21505594.2022.2073025 PMC 바로가기 [Article Type] Article
Epigenetic perspectives of COVID-19: Virus infection to disease progression and therapeutic controlResearch article Published on 2022-12-012022-10-05 Journal: Biochimica et biophysica acta. Molecular basis of [Category] COVID19(2023년), SARS, 변종, 신약개발, 유전자 메커니즘, 치료제, [키워드] ACE2 analysed antagonistic autophagy caused Cell cellular metabolism cellular processe Course COVID-19 death Disease progression enzyme Epigenetic epigenetics example expression profile function genes encoding Genome Host host cell IL-6 Infection investigated Laboratory Lipid mechanism membrane metabolic activity metabolic pathway methionine pathogen invasion patients Perspective progression rDNA Regulation replication mechanism ribosome S-adenosylmethionine SARS-CoV-2 sera social isolation the disease the patient therapeutic therapy tissue viral loads virus virus particle virus replication [DOI] 10.1016/j.bbadis.2022.166527 [Article Type] Research article
The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineageArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] approach Cell culture circulating comparable contribute COVID-19 determine experimental animal models fitness. G496S genetics monoclonal antibodies omicron Omicron BA.1 Omicron BA.2 pathogenicity phenotype predominant receptor-binding motif Replication SARS-CoV-2 SARS-CoV-2 variant sensitivity spike mutation therapeutic trajectory [DOI] 10.1080/22221751.2022.2111977 PMC 바로가기
Zinc pyrithione is a potent inhibitor of PL Pro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication아연 피리티온은 SARS-CoV-2 진입 및 복제를 생체 외에서 억제하는 PL Pro 및 카텝신 L 효소의 강력한 억제제입니다.Article Published on 2022-12-012022-09-11 Journal: Journal of Enzyme Inhibition and Medicinal Chemist [Category] COVID19(2023년), SARS, 치료제, [키워드] analogue Anti-SARS-CoV-2 Activity Antiviral antiviral activity Antiviral agents assays cathepsin L comparable complex complexes contrary COVID-19 effective enzyme Enzymes evaluated Ex vivo expressed human lung tissue in vitro inhibition inhibitor involved Ligand media Pro pyrithione Replication ruthenium SARS-CoV-2 SARS-CoV-2 entry stability synthesised therapeutic therapeutic agent Zinc Zinc complexes Zinc pyrithione zinc. [DOI] 10.1080/14756366.2022.2108417 PMC 바로가기 [Article Type] Article